These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15609146)

  • 1. Pricing and reimbursement of pharmaceuticals in Norway.
    Hågå A; Sverre JM
    Eur J Health Econ; 2002; 3(3):215-20. PubMed ID: 15609146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Physicians' experience with increased use of individual reimbursement for pharmaceuticals].
    Levorsen A; Kristiansen IS; Aasland OG
    Tidsskr Nor Laegeforen; 2008 Aug; 128(16):1829-32. PubMed ID: 18787593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing and reimbursement of drugs in Denmark.
    Møller Pedersen K
    Eur J Health Econ; 2003; 4(1):60-5. PubMed ID: 15609170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond.
    Danzon PM; Wilensky GR; Means KE
    Am J Manag Care; 2005 Mar; 11(3):173-80. PubMed ID: 15786856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of generic drug supply in France].
    Taboulet F; Haramburu F; Latry P
    Rev Epidemiol Sante Publique; 2003 Sep; 51(4):415-25. PubMed ID: 13679734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Consequences of changing from fixed amount payments to percentage payment of drugs].
    Berg SH; Aasmundstveit O; Saanum DT
    Tidsskr Nor Laegeforen; 1990 Oct; 110(26):3391-4. PubMed ID: 2256066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reimbursement of generics in Croatia: should more have been done?].
    Vukusić M
    Lijec Vjesn; 2010; 132(5-6):134-43. PubMed ID: 20677618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restrictions on the reimbursement policy with regard to retail marketing of medicinal products in Poland.
    Zimmermann A
    Acta Pol Pharm; 2013; 70(2):339-43. PubMed ID: 23614291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The budget control function of the Drug Reimbursement System].
    Pronk MH; Bonsel GJ; van der Kuy A
    Ned Tijdschr Geneeskd; 2002 Sep; 146(37):1729-33. PubMed ID: 12357873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.